Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients.
Evaluation of the literature concerning the various approaches for the treatment of Wilson's disease led to the conclusion that zinc sulphate might be a good choice because it is effective and relatively safe. Twenty seven patients were managed with zinc sulphate for a total period of 142 patients-years. The drug was administered in doses varying from 300 to 1200 mg/day. Of the 9 patients who were treated with zinc from the start, 8 improved and one died from severe cirrhosis. All 8 patients who were placed on zinc after intolerance to penicillamine did well on zinc therapy. Ten patients were changed to zinc after they had first been treated with penicillamine without developing signs of intolerance. Of this group 8 patients were kept on long-term zinc therapy, 2 were changed back to penicillamine because of personal preference. Signs of intolerance to zinc were not observed. All patients kept a diet containing about 1.2 mg of copper a day. Our experience supports the idea that zinc sulphate is a good choice for the treatment of Wilson's disease: the drug is effective, safe and cheap.
D003300:Copper / Q000097:blood; D006527:Hepatolenticular Degeneration / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D010396:Penicillamine / Q000009:adverse effects; D013431:Sulfates / Q000627:therapeutic use*; D015032:Zinc / Q000097:blood / Q000627:therapeutic use*; D019287:Zinc Sulfate
D013431:Sulfates; D019287:Zinc Sulfate; D003300:Copper; D010396:Penicillamine; D015032:Zinc